Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases

[Image: see text] Inhibition of cyclin-dependent kinases (CDKs) has emerged as an attractive strategy for the development of novel oncology therapeutics. Herein is described the utilization of an in vivo screening approach with integrated efficacy and tolerability parameters to identify candidate CD...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Paruch, Kamil, Dwyer, Michael P., Alvarez, Carmen, Brown, Courtney, Chan, Tin-Yau, Doll, Ronald J., Keertikar, Kerry, Knutson, Chad, McKittrick, Brian, Rivera, Jocelyn, Rossman, Randall, Tucker, Greg, Fischmann, Thierry, Hruza, Alan, Madison, Vincent, Nomeir, Amin A., Wang, Yaolin, Kirschmeier, Paul, Lees, Emma, Parry, David, Sgambellone, Nicole, Seghezzi, Wolfgang, Schultz, Lesley, Shanahan, Frances, Wiswell, Derek, Xu, Xiaoying, Zhou, Quiao, James, Ray A., Paradkar, Vidyadhar M., Park, Haengsoon, Rokosz, Laura R., Stauffer, Tara M., Guzi, Timothy J.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Chemical Society 2010
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4007794/
https://ncbi.nlm.nih.gov/pubmed/24900195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/ml100051d
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares